Patients will be randomized to one of the two treatments arms in a 2:1 ratio (168 patients in the tivozanib arm and 84 patients in the bevacizumab arm). RCC to inform our clinical development strategy in an effort to bring tivozanib to patients who will benefit most," Slichenmyer added.
FULL ARTICLE AT Pharmaceutical Industry News